Current Treatment Options for Metastatic Pancreatic Adenocarcinoma.

Şendur, Mehmet Ali Nahit

doi:10.4999/uhod.1142

Cited by 1 publication

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with DNA repair dysfunction, including BRCA mutations, benefit from platinum chemotherapy and PARP inhibitors (31). Limited success has been reported concerning the use of therapies, including gemcitabine (134). The use of folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) has been reported to exhibit comparably increased efficiency, although presenting with an increased toxicity (135).…”

Section: Discussionmentioning

confidence: 99%

“…The use of folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) has been reported to exhibit comparably increased efficiency, although presenting with an increased toxicity (135). FOLFIRINOX and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine have demonstrated benefit (134), while a modest improvement in survival has been observed with gemcitabine-erlotinib and FOLFIRINOX (135). The median overall survival for patients with metastatic pancreatic adenocarcinoma (mPDA) treated with first-line regimens remains as low as 1 year, indicating a significant need for effective later-line options, nab-paclitaxel being one such example (31).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A pancreatic adenocarcinoma mimicking hepatoid carcinoma of uncertain histogenesis: A case report and literature review

Iliesiu,

Toma,

Ciongariu

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

In rare cases, metastatic adenocarcinomas of different origin may exhibit the features of hepatoid carcinoma (HC), a rare malignant epithelial tumor, most commonly occurring in the ovaries and stomach, as well as in the pancreas and biliary ducts. A case of a 72-year-old female patient who developed a highly aggressive, poorly differentiated pancreatic ductal adenocarcinoma with peritoneal carcinomatosis, demonstrating hepatoid differentiation upon conventional hematoxylin and eosin staining is reported in the present study. The patient presented with severe abdominal pain, and the radiological investigations performed revealed ovarian and hepatic tumor masses and peritoneal lesions, which were surgically removed. The gross examination of the peritoneum and omentum revealed multiple solid, firm, grey-white nodules, diffusely infiltrating the adipose tissue. The microscopic examination revealed a malignant epithelial proliferation, composed of polygonal cells with abundant eosinophilic cytoplasm and irregular, pleomorphic nuclei. Certain cells presented with intracytoplasmic mucus inclusions, raising suspicion of a HC with an uncertain histogenesis. Immunohistochemical staining was performed, and the tumor cells were found to be positive for cytokeratin (CK)7, CK18 and mucin 5AC, whereas negative staining for CK20, caudal-type homeobox transcription factor 2, α-fetoprotein, paired box gene 8, GATA-binding protein 3 and Wilms tumor 1 were documented. Thus, the diagnosis of metastatic pancreatic adenocarcinoma was established. The main aim of the present study was to provide further knowledge concerning poorly differentiated metastatic adenocarcinoma resembling HC, emphasizing the histopathological and immunohistochemical features of these malignant lesions and raising awareness of the diagnostic difficulties that may arise, as well as the importance of the use immunohistochemistry in differentiating carcinomas of uncertain histogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%